Clinical trial of Shengmai capsules in the treatment of patients with chronic congestive heart failure
10.13699/j.cnki.1001-6821.2018.02.010
- VernacularTitle:生脉胶囊治疗慢性充血性心力衰竭的临床研究
- Author:
Xing LIU
1
;
Huan L(U)
Author Information
1. 广饶县人民医院心内科
- Keywords:
Shengmai capsule;
chronic congestive heart failure;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(2):127-130
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of Shengmai capsules in the treatment of chronic congestive heart failure.Methods Eighty-four patients with chronic congestive heart failure were randomly divided into control group and treatment group with 42 cases per group.Control group was given placebo 0.3 mg each time,tid,orally.Treatment group was given Shengmai capsule 0.3 mg each time,tid,orally.Two groups were treated for 2 weeks.The clinical efficacy,heart rate,left ventricular ejection fraction (LVEF),maximal velocity of bicuspid blood flow in the early (E),E/ maximal velocity of bicuspid blood flow in the advanced (E/A),pulmonary artery pressure (PAS),heart function echocardiographic multi-parameter scores (HF-EMPS) and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 90.47％ (38 cases/42 cases) and 73.81％ (31 cases/42 cases) with significant difference (P ＜ 0.05).After treatment,the main indexes in treatment and control groups were compared:heart rate were (66.54 ±7.02) and (72.12 ± 8.14) beat · min-1,LVEF were (46.03 ±5.56)％ and (41.26 ±5.12)％,E were(92.48 ±14.32)and(75.41 ± 13.62)cm · s-1,E/A were 1.65±0.34 and 1.35 ± 0.31,PAS were (24.85 ± 4.21) and (30.12 ± 4.22) mmHg,HF-EMPS were (7.03 ±1.12) and (7.68 ± 1.32)points with significant difference (all P ＜ 0.05).There were no adverse drug reactions occurred during the treatment in two groups.Conelusion Shengmai capsules have a definitive clinical efficacy and safety in the treatment of chronic congestive heart failure.
